Stay updated on Aptose Biosciences Press Releases
Sign up to get notified when there's something new on the Aptose Biosciences Press Releases page.

Latest updates to the Aptose Biosciences Press Releases page
- Check2 days agoChange DetectedAdded a new press release dated Mar 31, 2026: Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights. Deleted the Sep 22, 2025 press release: Aptose and Hanmi Pharmaceutical Extend Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML.SummaryDifference2%

- Check10 days agoChange DetectedAdded a new press release on Mar 23, 2026: 'Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement'. Removed an older press release from Aug 22, 2025: 'Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor'.SummaryDifference2%

- Check17 days agoChange DetectedAdded a Mar 19, 2026 press release announcing that ISS recommends voting FOR the Hanmi plan of arrangement; removed the Aug 18, 2025 press release summarizing early Tuspetinib data from the TUSCANY trial.SummaryDifference2%

- Check24 days agoNo Change Detected
- Check38 days agoChange DetectedAdded a new press release dated Feb 24, 2026: Aptose Biosciences Announces Amendment to Arrangement Agreement and Details of Postponed Special Meeting of Shareholders. Deleted the Aug 13, 2025 entry: Aptose Reports Second Quarter 2025 Results.SummaryDifference2%

- Check89 days agoChange DetectedFooter copyright year updated from 2025 to 2026 on the Press Releases page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check103 days agoChange DetectedAdded a new press release about rescheduling the shareholder meeting to approve the acquisition by Hanmi pending SEC clearance. Removed an older press release announcing enrollment for the 160 mg dosing cohort of the Tuspetinib Phase 1/2 TUSCANY trial.SummaryDifference2%

Stay in the know with updates to Aptose Biosciences Press Releases
Enter your email address, and we'll notify you when there's something new on the Aptose Biosciences Press Releases page.